Gary E. Borodic
Gary E. Borodic has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
David Hinkle
The authors have no financial or conflicts of interest to disclose
1 shared publicationDavid M. Hinkle
1 shared publicationEric A Johnson
1 shared publication- Eric A. Johnson
Department of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, USA
1 shared publication Martin A. Acquadro
Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA
1 shared publicationMartin Acquadro
1 shared publication
Latest Publications
- 1 May 2013
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 29 (3) , 225-226
Use of Fillers as Adjunct Therapy for the Treatment of Lower Face Hemifacial Spasm
The treatment of hemifacial spasm with periorbital injections of higher doses of botulinum toxin can create disfiguring and undesirable weakness in the lower face during active facial movements. The use of asymmetric hyaluronidate filler injections to the lower face provides a refinement allowing for a lowered neurotoxin dose. The filler creates a ballasting effect and involuntary facial movement. The conventional filler effect also further reduces asymmetric nasolabial folds and marionette lines. Fifteen of 18 patients with lower facial spasms found the filler toxin combination an improvement over neurotoxin alone.
- 1 May 2013
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 29 (3) , 225-226
Use of Fillers as Adjunct Therapy for the Treatment of Lower Face Hemifacial Spasm
The treatment of hemifacial spasm with periorbital injections of higher doses of botulinum toxin can create disfiguring and undesirable weakness in the lower face during active facial movements. The use of asymmetric hyaluronidate filler injections to the lower face provides a refinement allowing for a lowered neurotoxin dose. The filler creates a ballasting effect and involuntary facial movement. The conventional filler effect also further reduces asymmetric nasolabial folds and marionette lines. Fifteen of 18 patients with lower facial spasms found the filler toxin combination an improvement over neurotoxin alone.
- 1 July 2011
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 27 (4) , e87-e88
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Monoclonal antibody, ipilimumab, useful for treatment of metastatic melanoma, blocks CTLA-4 mediated T-cell suppression and can also cause a Graves ophthalmopathy like syndrome. Epidemiologic study has linked variant polymorphisms of CTLA-4 receptor gene to the presence of thyroid eye disease. The combination of these observations suggests CTLA-4 mediated T-cell functions are important to the pathogenesis of thyroid-associated eye disease.
- 1 July 2011
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 27 (4) , e87-e88
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Monoclonal antibody, ipilimumab, useful for treatment of metastatic melanoma, blocks CTLA-4 mediated T-cell suppression and can also cause a Graves ophthalmopathy like syndrome. Epidemiologic study has linked variant polymorphisms of CTLA-4 receptor gene to the presence of thyroid eye disease. The combination of these observations suggests CTLA-4 mediated T-cell functions are important to the pathogenesis of thyroid-associated eye disease.
- 1 February 2007
- Published by Elsevier in Facial Plastic Surgery Clinics of North America
- Vol. 15 (1) , 11-16
Botulinum Toxin, Immunologic Considerations with Long-Term Repeated Use, with Emphasis on Cosmetic Applications
- 1 February 2007
- Published by Elsevier in Facial Plastic Surgery Clinics of North America
- Vol. 15 (1) , 11-16
Botulinum Toxin, Immunologic Considerations with Long-Term Repeated Use, with Emphasis on Cosmetic Applications
- 1 February 2002
- Published by Elsevier in The Journal of Pain
- Vol. 3 (1) , 21-27
The use of botulinum toxin for the treatment of chronic facial pain
- 1 February 2002
- Published by Elsevier in The Journal of Pain
- Vol. 3 (1) , 21-27
The use of botulinum toxin for the treatment of chronic facial pain
- 1 August 2001
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 10 (8) , 1531-1544
Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects
Botulinum toxin (BTX) injections are a well-recognised therapeutic modality for the treatment of regional involuntary muscle disorders and recently BTX has been used for treatment of pain and inflammatory disorders. The primary purpose of this review is to discuss the mechanism of action of therapeutic BTX in light of both the traditional understanding of BTX pharmacological effects as well as new observations. The review will deal with clinical observations and relevant animal experimentation. The data and hypotheses presented are not only relevant to botulinum toxin technology but will certainly prove important in the basic mechanisms of some of the diseases where botulinum toxin has been successfully applied. BTX used clinically comprises botulinum neurotoxin (BoNT) complexed with non-toxic proteins. The non-toxic components of the BTX complexes stabilise the labile BoNT during purification and formulation as a therapeutic. The complex proteins may also have unrecognised clinical significance such as s...
- 1 August 2001
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 10 (8) , 1531-1544
Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects
Botulinum toxin (BTX) injections are a well-recognised therapeutic modality for the treatment of regional involuntary muscle disorders and recently BTX has been used for treatment of pain and inflammatory disorders. The primary purpose of this review is to discuss the mechanism of action of therapeutic BTX in light of both the traditional understanding of BTX pharmacological effects as well as new observations. The review will deal with clinical observations and relevant animal experimentation. The data and hypotheses presented are not only relevant to botulinum toxin technology but will certainly prove important in the basic mechanisms of some of the diseases where botulinum toxin has been successfully applied. BTX used clinically comprises botulinum neurotoxin (BoNT) complexed with non-toxic proteins. The non-toxic components of the BTX complexes stabilise the labile BoNT during purification and formulation as a therapeutic. The complex proteins may also have unrecognised clinical significance such as s...